Satellite Bio launched Wednesday with $110 million in previously undisclosed Seed and Series A investments led by aMoon Growth.

The U.S. Food and Drug Administration declined to approve Enzyvant’s regenerative tissue therapy for a rare immunodeficiency disorder and raised concerns about the privately held drug developer’s manufacturing.

Roche and its subsidiaries are ramping up treatment options for multiple sclerosis. In April, the company acquired a regenerative therapy program for MS from Inception Sciences. Now, Roche’s Genentech announced new data showcasing the efficacy of Ocrevus in relapsing multiple sclerosis (RMS).